Compare Bristol-Myers Squibb Co (BMY) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Invesco Preferred ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.77 (market cap $129.94B), while Invesco Preferred ETF trades at $10.68. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while Invesco Preferred ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals.
| BMY | PGX | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | — |
52-Week High | $65.89 | $11.87 |
52-Week Low | $42.60 | $10.65 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
PGX trades at $10.675, up 0.23% today, with a bearish technical outlook indicated by moving averages. Recent corporate actions include dividends declared for H1-26 and H2-26. Financial ratios such as P/E and P/B are not available in the provided data, limiting fundamental assessment.
The stock faces headwinds from bearish technical signals and lack of recent financial data. Investment appeal may hinge on upcoming earnings clarity and sector performance, with risks including market volatility and competitive pressures in its industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
